Information Provided By: 
Fly News Breaks for May 31, 2017
SUPN
May 31, 2017 | 05:41 EDT
Jefferies analyst David Steinberg raised his price target for Supernus Pharmaceuticals to $45 citing "robust" early Trokendi in migraine prescription trends. The analyst increased his FY17-FY20 Trokendi estimates by $12M, $45M, $67M, and $80M, which he believes could prove conservative. Steinberg views the early launch of the drug as "impressive" and keeps a Buy rating on the shares.
News For SUPN From the Last 2 Days
There are no results for your query SUPN
